However, deregulation of the p16-CDK/cyclin D-pRb pathway has been described in NB (Diccianni et al, 1996; Easton et al, 1998) and, interestingly, contradictory results have been reported concerning the correlation between clinical outcome in NB and CDKN2A/p16INK4a expression (Takita et al, 1998; Omura-Minamisawa et al, 2001). The gene discussed is CDKN2A; the disease is neuroblastoma.